1 Henderson, M. X., Changolkar, L., Trojanowski, J. Q. & Lee, V. M. Y. LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons. Journal of Parkinson's disease, doi:10.3233/JPD-212562 (2021).
2 Henderson, M. X. et al. Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological alpha-Synuclein Insult. Neuron 105, 822-836 e827, doi:10.1016/j.neuron.2019.12.004 (2020).
3 Henderson, M. X. et al. Characterization of novel conformation-selective alpha-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease. Neurobiology of disease 136, 104712, doi:10.1016/j.nbd.2019.104712 (2020).
4 Henderson, M. X., Peng, C., Trojanowski, J. Q. & Lee, V. M. Y. LRRK2 activity does not dramatically alter alpha-synuclein pathology in primary neurons. Acta neuropathologica communications 6, 45, doi:10.1186/s40478-018-0550-0 (2018).
5 Henderson, M. X. et al. Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies. J Neurosci 37, 5870-5884, doi:10.1523/JNEUROSCI.2705-16.2017 (2017).